ImmunityBio (IBRX) vs Immunovant (IMVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmunityBio (IBRX) has outperformed Immunovant (IMVT) over the past year, gaining 189.4% versus a gain of 40.6%. Over five years, IMVT leads with a +308.9% price change compared with -7.4% for IBRX. Immunovant is the larger company by market cap ($6.57 billion vs $6.40 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | IMVT |
|---|---|---|
| Share price | $6.02 | $31.77 |
| Market cap | $6.40B | $6.57B |
| 1-day change | -8.37% | -2.31% |
| YTD return | +204.04% | +24.98% |
| 1-year return | +189.42% | +40.64% |
| 5-year return | -7.38% | +308.88% |
| EPS (TTM) | $-1.06 | $-2.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | — |
| Revenue growth (YoY) | +668.31% | — |
| Net income (latest FY) | $-351.40M | $-505.61M |
| Gross margin | 99.34% | — |
| Operating margin | -226.00% | — |
| Net margin | -310.18% | — |
| 52-week high | $12.43 | $45.42 |
| 52-week low | $1.95 | $21.93 |
| Distance from 52-week high | -51.57% | -30.05% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +136.71% | +53.07% |
| Average volume | 12.97M | 1.42M |
| Shares outstanding | 1.06B | 206.95M |
| Employees | 684 | 315 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed IMVT by 148.8 percentage points over the past year.
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
IBRX vs IMVT FAQ
Which is bigger, ImmunityBio or Immunovant?
Immunovant (IMVT) is larger, with a market capitalization of $6.57B compared with $6.40B for ImmunityBio (IBRX).
Which stock has performed better over the past year, IBRX or IMVT?
IBRX returned +189.42% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Immunovant in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.